Cargando…

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

BACKGROUND: Alpha glucosidase inhibitor (GI) attenuates postprandial hyperglycemia (PPH) and reduces the risk of cardiovascular events in patients with impaired glucose tolerance or type 2 diabetes. Dipeptidyl peptidase 4 (DPP-4) inhibitors also attenuate PPH. PPH is one of the factors leading to en...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamura, Kazufumi, Oe, Hiroki, Kihara, Hajime, Shimada, Kenei, Fukuda, Shota, Watanabe, Kyoko, Takagi, Tsutomu, Yunoki, Kei, Miyoshi, Toru, Hirata, Kumiko, Yoshikawa, Junichi, Ito, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4149239/ https://www.ncbi.nlm.nih.gov/pubmed/25074318 http://dx.doi.org/10.1186/s12933-014-0110-2

Ejemplares similares

Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
por: Oe, Hiroki, et al.
Publicado: (2015)

Adding thiazide to a renin–angiotensin blocker improves left ventricular relaxation and improves heart failure in patients with hypertension
por: Ito, Hiroshi, et al.
Publicado: (2012)

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study
por: Osonoi, Takeshi, et al.
Publicado: (2020)

Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases
por: Kubo, Ayano, et al.
Publicado: (2020)

Parachute-Like Structure Oscillating Between Left Ventricular Outflow Tract and Sinus of Valsalva
por: Kono, Yasushi, et al.
Publicado: (2021)

Clinical Use of DPP-4 Inhibitors
por: Gallwitz, Baptist
Publicado: (2019)

Renoprotective Effects of DPP-4 Inhibitors
por: Kawanami, Daiji, et al.
Publicado: (2021)

Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

The effect of luseogliflozin and alpha-glucosidase inhibitor on heart failure with preserved ejection fraction in diabetic patients: rationale and design of the MUSCAT-HF randomised controlled trial
por: Ejiri, Kentaro, et al.
Publicado: (2019)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
por: Liu, Jinglong, et al.
Publicado: (2014)

PARP inhibitors are not all equal
por: Dent, Paul
Publicado: (2013)

Adding thiazide to a rennin-angiotensin blocker regimen to improve left ventricular relaxation in diabetes and nondiabetes patients with hypertension
por: Takami, Takeshi, et al.
Publicado: (2012)

Acute myocardial infarction associated to DPP-4 inhibitors
por: Nunes, J P L, et al.
Publicado: (2014)

Use of DPP-4 inhibitors in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

α-Glucosidase inhibitors and their use in clinical practice
por: Derosa, Giuseppe, et al.
Publicado: (2012)

α-Glucosidase Inhibitors from Vauquelinia corymbosa
por: Flores-Bocanegra, Laura, et al.
Publicado: (2015)

Characterizing the selectivity of ER α-glucosidase inhibitors
por: O’Keefe, Sarah, et al.
Publicado: (2019)

Carba-cyclophellitols Are Neutral Retaining-Glucosidase Inhibitors
por: Beenakker, Thomas J. M., et al.
Publicado: (2017)

Flavonoids as Human Intestinal α-Glucosidase Inhibitors
por: Barber, Elizabeth, et al.
Publicado: (2021)

DPP-IV Inhibitor–Associated Angioedema in Patient With Known History of ACE Inhibitor Angioedema
por: Ejikeme, Chidinma, et al.
Publicado: (2021)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Alogliptin: a new addition to the class of DPP-4 inhibitors
por: Andukuri, Radha, et al.
Publicado: (2009)

Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
por: Haluzík, Martin, et al.
Publicado: (2013)

Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
por: Kang, Seon Mee, et al.
Publicado: (2021)

Synergistic effect of α‐glucosidase inhibitors and dipeptidyl peptidase 4 inhibitor treatment
por: Horikawa, Yukio, et al.
Publicado: (2010)

The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
por: Schernthaner, Guntram, et al.
Publicado: (2014)

Impacts of the DPP-4 Inhibitor Saxagliptin and SGLT-2 Inhibitor Dapagliflozin on the Gonads of Diabetic Mice
por: Alshamrani, Ali A., et al.
Publicado: (2023)

Aortic arch plaque morphology in patients with coronary artery disease undergoing coronary computed tomography angiography with wide-volume scan
por: Otsuka, Kenichiro, et al.
Publicado: (2022)

QSAR Studies on Andrographolide Derivatives as α-Glucosidase Inhibitors
por: Xu, Jun, et al.
Publicado: (2010)

A novel method for screening beta-glucosidase inhibitors
por: Pandey, Sony, et al.
Publicado: (2013)

α-Glucosidase inhibitors from the bark of Mangifera mekongensis
por: Nguyen, Hai Xuan, et al.
Publicado: (2016)

Diversity of marine bacteria producing beta-glucosidase inhibitors
por: Pandey, Sony, et al.
Publicado: (2013)

Untapped diamonds for untamed diabetes: The α-glucosidase inhibitors
por: Kalra, Sanjay, et al.
Publicado: (2014)

Correction to: Characterizing the selectivity of ER α-glucosidase inhibitors
Publicado: (2023)

Combined treatment with DPP-4 inhibitor linagliptin and SGLT2 inhibitor empagliflozin attenuates neointima formation after vascular injury in diabetic mice
por: Takahashi, Hiroyuki, et al.
Publicado: (2019)

Synthesis and Comparative Structure–Activity Study of Carbohydrate-Based Phenolic Compounds as α-Glucosidase Inhibitors and Antioxidants
por: Machida, Shota, et al.
Publicado: (2019)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2013)

DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors
por: Dicker, Dror
Publicado: (2011)

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto, Miyako
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hnfbat2r8mulmfpleo6uk4pkut